$12.73
-0.37 (-2.82%)
Open$14.00
Previous Close$13.10
Day High$14.00
Day Low$12.70
52W High$17.92
52W Low$9.41
Volume—
Avg Volume789.6K
Market Cap27.40M
P/E Ratio—
EPS$-1.40
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+80.7% upside
Current
$12.73
$12.73
Target
$23.00
$23.00
$15.62
$23.00 avg
$28.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.59M | 3.48M | 3.01M |
| Net Income | 732.2K | 573.7K | 520.4K |
| Profit Margin | 20.4% | 16.5% | 17.3% |
| EBITDA | 1.09M | 1.00M | 849.7K |
| Free Cash Flow | 537.7K | 589.4K | 453.2K |
| Rev Growth | +3.4% | -1.6% | +9.6% |
| Debt/Equity | 0.28 | 0.26 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |